Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression.
breast cancer
cell signaling
epigenetics
estrogen receptor alpha
estrogen receptor beta
extracellular matrix
molecular targeting
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
revised:
26
07
2024
received:
12
06
2024
accepted:
02
09
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
aheadofprint
Résumé
Cancer remains a significant global health concern. Breast cancer is a multifaceted and prevalent disease influenced by several factors, among which estrogen receptors (ERs) and the extracellular matrix (ECM) play pivotal roles. ERs, encompassing ERα and ERβ, exert significant diversity on tumor behavior, cell signaling, invasion, and metastatic potential, thus guiding breast cancer prognosis. Understanding the multifunctional connections between ERs and ECM that mediate the dynamics of tumor microenvironment is vital for unraveling the complexity of breast cancer pathobiology and identifying novel therapeutic targets. This critical review delves into the intricate nature of ERs, emphasizing their structural isoforms and the consequential impact on breast cancer outcomes. A detailed examination of ER-mediated cell signaling pathways reveals how differential expression of ERα and ERβ isoforms influence breast cancer cell behavior. The functional ERs-matrix interactions emerge as a pivotal factor in modulating epigenetic mechanisms of breast cancer cells, orchestrating changes in cellular phenotype and expression patterns of matrix modulators. Specifically, ERα isoforms are shown to regulate ECM signaling cascades, while the effects of ECM components on ERα activity highlight a bidirectional regulatory axis. The diversity of ERβ isoforms is also highlighted, illustrating their distinct contribution to ECM-mediated cellular responses. This review underscores the complex interplay between ERα/β isoforms and the ECM, shedding light onto the potential therapeutic strategies targeting these interactions to improve breast cancer management.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union
ID : 101130985
Organisme : University of Patras
Informations de copyright
© 2024 The Author(s). The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
World Health Organization (WHO) (2023) Global Breast Cancer Initiative Implementation Framework: Assessing, Strengthening and Scaling‐Up of Services for the Early Detection and Management of Breast Cancer. WHO, Geneva.
Piperigkou Z & Karamanos NK (2020) Estrogen receptor‐mediated targeting of the extracellular matrix network in cancer. Semin Cancer Biol 62, 116–124.
Altwegg KA & Vadlamudi RK (2021) Role of estrogen receptor coregulators in endocrine resistant breast cancer. Explor Target Antitumor Ther 2, 385–400.
Karamanos NK, Theocharis AD, Piperigkou Z, Manou D, Passi A, Skandalis SS, Vynios DH, Orian‐Rousseau V, Ricard‐Blum S, Schmelzer CEH et al. (2021) A guide to the composition and functions of the extracellular matrix. FEBS J 288, 6850–6912.
Franchi M, Piperigkou Z, Mastronikolis NS & Karamanos N (2024) Extracellular matrix biomechanical roles and adaptation in health and disease. FEBS J 291, 430–440.
Karamanos NK, Piperigkou Z, Passi A, Götte M, Rousselle P & Vlodavsky I (2021) Extracellular matrix‐based cancer targeting. Trends Mol Med 27, 1000–1013.
Jurj A, Ionescu C, Berindan‐Neagoe I & Braicu C (2022) The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes? J Exp Clin Cancer Res 41, 276.
Cirillo F, Pellegrino M, Talia M, Perrotta ID, Rigiracciolo DC, Spinelli A, Scordamaglia D, Muglia L, Guzzi R, Miglietta AM et al. (2021) Estrogen receptor variant ERα46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer‐associated fibroblasts. Clin Transl Med 11, e516.
Chantalat E, Boudou F, Laurell H, Palierne G, Houtman R, Melchers D, Rochaix P, Filleron T, Stella A, Burlet‐Schiltz O et al. (2016) The AF‐1‐deficient estrogen receptor ERα46 isoform is frequently expressed in human breast tumors. Breast Cancer Res 18, 123.
Thiebaut C, Konan H‐P, Guerquin M‐J, Chesnel A, Livera G, Le Romancer M & Dumond H (2020) The role of ERα36 in development and tumor malignancy. Int J Mol Sci 21, 4116.
Zhu H, Huang Y, Su H, Ma Y, Tao Y, Liao D, Liu Y & Feng Z (2018) Identification of a novel human estrogen receptor‐α splice variant able to enhance malignant biological behaviors of breast cancer cells. Oncol Lett 15, 5339–5344.
Pagano MT, Ortona E & Dupuis ML (2020) A role for estrogen receptor alpha36 in cancer progression. Front Endocrinol 11, 506.
Rusidzé M, Adlanmérini M, Chantalat E, Raymond‐Letron I, Cayre S, Arnal J‐F, Deugnier M‐A & Lenfant F (2021) Estrogen receptor‐α signaling in post‐natal mammary development and breast cancers. Cell Mol Life Sci 78, 5681–5705.
Clusan L, Ferrière F, Flouriot G & Pakdel F (2023) A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci 24, 6834.
Yan S, Wang J, Chen H, Zhang D & Imam M (2023) Divergent features of ERβ isoforms in triple negative breast cancer: progress and implications for further research. Front Cell Dev Biol 11, 1240386.
Papoutsi Z, Zhao C, Putnik M, Gustafsson J‐Å & Dahlman‐Wright K (2009) Binding of estrogen receptor α/β heterodimers to chromatin in MCF‐7 cells. J Mol Endocrinol 43, 65–72.
Moisand A, Madéry M, Boyer T, Domblides C, Blaye C & Larmonier N (2023) Hormone receptor signaling and breast cancer resistance to anti‐tumor immunity. Int J Mol Sci 24, 15048.
Kaleem M, Perwaiz M, Nur SM, Abdulrahman AO, Ahmad W, Al‐Abbasi FA, Kumar V, Kamal MA & Anwar F (2022) Epigenetics of triple‐negative breast cancer via natural compounds. Curr Med Chem 29, 1436–1458.
Zolota V, Tzelepi V, Piperigkou Z, Kourea H, Papakonstantinou E, Argentou M‐I & Karamanos NK (2021) Epigenetic alterations in triple‐negative breast cancer—the critical role of extracellular matrix. Cancer 13, 713.
Piperigkou Z & Karamanos NK (2019) Dynamic interplay between miRNAs and the extracellular matrix influences the tumor microenvironment. Trends Biochem Sci 44, 1076–1088.
Kim A, Mo K, Kwon H, Choe S, Park M, Kwak W & Yoon H (2023) Epigenetic regulation in breast cancer: insights on epidrugs. Epigenomes 7, 6.
Feser R, Opperman RM, Maiti S & Majumder M (2022) MicroRNAs: the master regulators of the breast cancer tumor microenvironment. In Handbook of Oxidative Stress in Cancer: Therapeutic Aspects (Chakraborti S, ed.), pp. 1–23. Singapore, Springer.
Sepúlveda F, Mayorga‐Lobos C, Guzmán K, Durán‐Jara E & Lobos‐González L (2023) EV‐miRNA‐mediated intercellular communication in the breast tumor microenvironment. Int J Mol Sci 24, 13085.
Piperigkou Z, Franchi M, Götte M & Karamanos NK (2017) Estrogen receptor beta as epigenetic mediator of miR‐10b and miR‐145 in mammary cancer. Matrix Biol 64, 94–111.
Piperigkou Z, Franchi M, Riethmüller C, Götte M & Karamanos NK (2020) miR‐200b restrains EMT and aggressiveness and regulates matrix composition depending on ER status and signaling in mammary cancer. Matrix Biol Plus 6–7, 100024.
Bouris P, Skandalis SS, Piperigkou Z, Afratis N, Karamanou K, Aletras AJ, Moustakas A, Theocharis AD & Karamanos NK (2015) Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol 43, 42–60.
Kousidou OC, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN & Karamanos NK (2008) Estradiol–estrogen receptor: a key interplay of the expression of syndecan‐2 and metalloproteinase‐9 in breast cancer cells. Mol Oncol 2, 223–232.
Garan LAW, Xiao Y & Lin W‐C (2022) 14‐3‐3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci USA 119, e2209211119.
Xiang Y, Li JP, Guo W, Wang D‐Q, Yao A, Zhang H‐M, Huang F, Li H‐H, Dai Z‐T, Zhang Z‐J et al. (2019) Novel interactions between ERα‐36 and STAT3 mediate breast cancer cell migration. Cell Commun Signal 17, 93.
Omarjee S, Jacquemetton J, Poulard C, Rochel N, Dejaegere A, Chebaro Y, Treilleux I, Marangoni E, Corbo L & Romancer ML (2017) The molecular mechanisms underlying the ERα‐36‐mediated signaling in breast cancer. Oncogene 36, 2503–2514.
Méndez‐García LA, Nava‐Castro KE, Ochoa‐Mercado TDL, Palacios‐Arreola MI, Ruiz‐Manzano RA, Segovia‐Mendoza M, Solleiro‐Villavicencio H, Cázarez‐Martínez C & Morales‐Montor J (2019) Breast cancer metastasis: are cytokines important players during its development and progression? J Interferon Cytokine Res 39, 39–55.
Afratis NA, Bouris P, Skandalis SS, Multhaupt HA, Couchman JR, Theocharis AD & Karamanos NK (2017) IGF‐IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules. Sci Rep 7, 40138.
Babyshkina N, Dronova T, Erdyneeva D, Gervas P & Cherdyntseva N (2021) Role of TGF‐β signaling in the mechanisms of tamoxifen resistance. Cytokine Growth Factor Rev 62, 62–69.
Mao X‐D, Wei X, Xu T, Li T‐P & Liu K‐S (2022) Research progress in breast cancer stem cells: characterization and future perspectives. Am J Cancer Res 12, 3208–3222.
Skandalis SS, Afratis N, Smirlaki G, Nikitovic D, Theocharis AD, Tzanakakis GN & Karamanos NK (2014) Cross‐talk between estradiol receptor and EGFR/IGF‐IR signaling pathways in estrogen‐responsive breast cancers: focus on the role and impact of proteoglycans. Matrix Biol 35, 182–193.
Tsonis AI, Afratis N, Gialeli C, Ellina M, Piperigkou Z, Skandalis SS, Theocharis AD, Tzanakakis GN & Karamanos NK (2013) Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin‐like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS J 280, 2248–2259.
Voudouri K, Nikitovic D, Berdiaki A, Kletsas D, Karamanos NK & Tzanakakis GN (2016) IGF‐I/EGF and E2 signaling crosstalk through IGF‐IR conduit point affects breast cancer cell adhesion. Matrix Biol 56, 95–113.
Konan H‐P, Kassem L, Omarjee S, Surmieliova‐Garnès A, Jacquemetton J, Cascales E, Rezza A, Trédan O, Treilleux I, Poulard C et al. (2020) ERα‐36 regulates progesterone receptor activity in breast cancer. Breast Cancer Res 22, 50.
Lugo‐Cintrón KM, Gong MM, Ayuso JM, Tomko LA, Beebe DJ, Virumbrales‐Muñoz M & Ponik SM (2020) Breast fibroblasts and ECM components modulate breast cancer cell migration through the secretion of MMPs in a 3D microfluidic co‐culture model. Cancer 12, 1173.
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, Zhang Z, Yang S & Xiao M (2023) Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer 22, 48.
Jena MK & Janjanam J (2018) Role of extracellular matrix in breast cancer development: a brief update. F1000Res 7, 274.
Afratis NA, Klepfish M, Karamanos NK & Sagi I (2018) The apparent competitive action of ECM proteases and cross‐linking enzymes during fibrosis: applications to drug discovery. Adv Drug Deliv Rev 129, 4–15.
Jallow F, O'Leary KA, Rugowski DE, Guerrero JF, Ponik SM & Schuler LA (2019) Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer. Oncogene 38, 6913–6925.
Motta JM, Hassan H & Ibrahim SA (2023) Revisiting the syndecans: master signaling regulators with prognostic and targetable therapeutic values in breast carcinoma. Cancer 15, 1794.
Huang Y, Hong W & Wei X (2022) The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol 15, 129.
Park M, Lee SH, Bui QT, Kim Y‐M & Kang KW (2022) The essential role of YAP in ERα36‐mediated proliferation and the epithelial‐mesenchymal transition in MCF‐7 breast cancer cells. Front Pharmacol 13, 1057276.
Melone V, Salvati A, Brusco N, Alexandrova E, D'Agostino Y, Palumbo D, Palo L, Terenzi I, Nassa G, Rizzo F et al. (2023) Functional relationships between long non‐coding RNAs and estrogen receptor alpha: a new frontier in hormone‐responsive breast cancer management. Int J Mol Sci 24, 1145.
Howard EW & Yang X (2018) microRNA regulation in estrogen receptor‐positive breast cancer and endocrine therapy. Biol Proced Online 20, 17.
Dziechciowska I, Dąbrowska M, Mizielska A, Pyra N, Lisiak N, Kopczyński P, Jankowska‐Wajda M & Rubiś B (2023) miRNA expression profiling in human breast cancer diagnostics and therapy. Curr Issues Mol Biol 45, 9500–9525.
Song HK & Kim SY (2021) The role of sex‐specific long non‐coding RNAs in cancer prevention and therapy. J Cancer Prev 26, 98–109.
Abdel‐hamid NR, Mohammed EA, Toraih EA, Kamel MM, Abdelhafiz AS & Badr FM (2023) Circulating ESR1, long non‐coding RNA HOTAIR and microRNA‐130a gene expression as biomarkers for breast cancer stage and metastasis. Sci Rep 13, 22654.
Botti G, Scognamiglio G, Aquino G, Liguori G & Cantile M (2019) LncRNA HOTAIR in tumor microenvironment: what role? Int J Mol Sci 20, 2279.
Liu L, Wang Y, Lin P, Zhang X, Cheng W, Liu S, Chen C, Hung Y, Jan C, Chang L et al. (2019) Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. Int J Cancer 145, 2478–2487.
Raju GSR, Pavitra E, Bandaru SS, Varaprasad GL, Nagaraju GP, Malla RR, Huh YS & Han Y‐K (2023) HOTAIR: a potential metastatic, drug‐resistant and prognostic regulator of breast cancer. Mol Cancer 22, 65.
DiGiacomo JW, Godet I, Trautmann‐Rodriguez M & Gilkes DM (2021) Extracellular matrix–bound FGF2 mediates estrogen receptor signaling and therapeutic response in breast cancer. Mol Cancer Res 19, 136–149.
Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA & Lupu R (2022) Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α6β1 drives endocrine resistance in breast cancer cells. Aging 14, 1200–1213.
Barros DPMD, André AN, Aru B, Simsek T & Demirel GY (2021) 17β‐Estradiol modulates the expression of CD44 and CD326 in estrogen‐sensitive breast cancer cells. Research Square. doi: 10.21203/rs.3.rs‐270944/v1
Dzobo K & Dandara C (2023) The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis. Biomimetics 8, 146.
Xu R, Yin P, Wei J & Ding Q (2023) The role of matrix stiffness in breast cancer progression: a review. Front Oncol 13, 1284926.
Barcus CE, O'Leary KA, Brockman JL, Rugowski DE, Liu Y, Garcia N, Yu M, Keely PJ, Eliceiri KW & Schuler LA (2017) Elevated collagen‐I augments tumor progressive signals, intravasation and metastasis of prolactin‐induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res 19, 9.
Barcus CE, Holt EC, Keely PJ, Eliceiri KW & Schuler LA (2015) Dense collagen‐I matrices enhance pro‐tumorigenic estrogen‐prolactin crosstalk in MCF‐7 and T47D breast cancer cells. PLoS One 10, e0116891.
Moreira AM, Pereira J, Melo S, Fernandes MS, Carneiro P, Seruca R & Figueiredo J (2020) The extracellular matrix: an accomplice in gastric cancer development and progression. Cells 9, 394.
Muncie JM & Weaver VM (2018) The physical and biochemical properties of the extracellular matrix regulate cell fate. Curr Top Dev Biol 130, 1–37.
Barbouri D, Afratis N, Gialeli C, Vynios DH, Theocharis AD & Karamanos NK (2014) Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol 4, 4.
Hassan N, Bückreiß N, Efing J, Schulz‐Fincke M, König P, Greve B, Bendas G & Götte M (2023) The heparan sulfate proteoglycan syndecan‐1 triggers breast cancer cell‐induced coagulability by induced expression of tissue factor. Cells 12, 910.
Siersbæk R, Kumar S & Carroll JS (2018) Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer. Genes Dev 32, 1141–1154.
Nagandla H & Thomas C (2024) Estrogen signals through ERβ in breast cancer; what we have learned since the discovery of the receptor. Receptors 3, 182–200.
Sellitto A, D'Agostino Y, Alexandrova E, Lamberti J, Pecoraro G, Memoli D, Rocco D, Coviello E, Giurato G, Nassa G et al. (2020) Insights into the role of estrogen receptor β in triple‐negative breast cancer. Cancer 12, 1477.
Leung Y‐K, Mak P, Hassan S & Ho S‐M (2006) Estrogen receptor (ER)‐β isoforms: a key to understanding ER‐β signaling. Proc Natl Acad Sci USA 103, 13162–13167.
Yan S, Dey P, Ziegler Y, Jiao X, Kim SH, Katzenellenbogen JA & Katzenellenbogen BS (2021) Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer. Breast Cancer Res Treat 185, 281–292.
Gustafsson J‐A, Strom A & Warner M (2019) Update on ERbeta. J Steroid Biochem Mol Biol 191, 105312.
Piperigkou Z, Bouris P, Onisto M, Franchi M, Kletsas D, Theocharis AD & Karamanos NK (2016) Estrogen receptor beta modulates breast cancer cells functional properties, signaling and expression of matrix molecules. Matrix Biol 56, 4–23.
Piperigkou Z, Koutsandreas A, Franchi M, Zolota V, Kletsas D, Passi A & Karamanos NK (2022) ESR2 drives mesenchymal‐to‐epithelial transition in triple‐negative breast cancer and tumorigenesis in vivo. Front Oncol 12, 917633.
Lindberg K, Ström A, Lock JG, Gustafsson J, Haldosén L & Helguero LA (2010) Expression of estrogen receptor β increases integrin α1 and integrin β1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 222, 156–167.
Wen P, Li J, Wen Z, Guo X, Ma G, Hu S, Xu J, Zhao H, Li R, Liu Y et al. (2024) MICAL‐L2, as an estrogen‐responsive gene, is involved in ER‐positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway. Biochem Pharmacol 225, 116256.
Kyriakopoulou K, Riti E, Piperigkou Z, Koutroumanou Sarri K, Bassiony H, Franchi M & Karamanos NK (2020) ΕGFR/ERβ‐mediated cell morphology and invasion capacity are associated with matrix culture substrates in breast cancer. Cells 9, 2256.
Kyriakopoulou K, Kefali E, Piperigkou Z, Riethmüller C, Greve B, Franchi M, Götte M & Karamanos NK (2022) EGFR is a pivotal player of the E2/ERβ – mediated functional properties, aggressiveness, and stemness in triple‐negative breast cancer cells. FEBS J 289, 1552–1574.
Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M & Gustafsson J‐Å (2014) Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci USA 111, 1933–1938.
Cantile M, Cerrone M, Di Bonito M, Moccia P, Tracey M, Ferrara G & Budillon A (2023) Endocrine nuclear receptors and long non‐coding RNAs reciprocal regulation in cancer (review). Int J Oncol 64, 7.
Mozdarani H, Ezzatizadeh V & Rahbar Parvaneh R (2020) The emerging role of the long non‐coding RNA HOTAIR in breast cancer development and treatment. J Transl Med 18, 152.
Tang Z, Kang B, Li C, Chen T & Zhang Z (2019) GEPIA2: an enhanced web server for large‐scale expression profiling and interactive analysis. Nucleic Acids Res 47, W556–W560.
Győrffy B (2024) Integrated analysis of public datasets for the discovery and validation of survival‐associated genes in solid tumors. Innovation 5, 100625.